These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

763 related articles for article (PubMed ID: 28814980)

  • 21. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
    Zhao B; He T
    Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD positive AML, both
    Li J; Liao D; Wang F; Wang Z; Li Y; Xiong Y; Niu T
    Leuk Lymphoma; 2022 May; 63(5):1167-1179. PubMed ID: 34865571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ginsenoside Rg1 Inhibits Cell Proliferation and Induces Markers of Cell Senescence in CD34+CD38- Leukemia Stem Cells Derived from KG1α Acute Myeloid Leukemia Cells by Activating the Sirtuin 1 (SIRT1)/Tuberous Sclerosis Complex 2 (TSC2) Signaling Pathway.
    Tang YL; Zhang CG; Liu H; Zhou Y; Wang YP; Li Y; Han YJ; Wang CL
    Med Sci Monit; 2020 Feb; 26():e918207. PubMed ID: 32037392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metformin as an Enhancer for the Treatment of Chemoresistant CD34+ Acute Myeloid Leukemia Cells.
    Krastinaite I; Charkavliuk S; Navakauskiene R; Borutinskaite VV
    Genes (Basel); 2024 May; 15(5):. PubMed ID: 38790277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway.
    Zhou J; Zhang C; Sui X; Cao S; Tang F; Sun S; Wang S; Chen B
    Invest New Drugs; 2018 Aug; 36(4):571-580. PubMed ID: 29504068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2.
    Xu B; Wang S; Li R; Chen K; He L; Deng M; Kannappan V; Zha J; Dong H; Wang W
    Cell Death Dis; 2017 May; 8(5):e2797. PubMed ID: 28518151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy.
    Lun Y; Yang JJ; Wu Y
    J Clin Pharm Ther; 2017 Dec; 42(6):786-789. PubMed ID: 28646565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Silencing of the DNA damage repair regulator PPP1R15A sensitizes acute myeloid leukemia cells to chemotherapy.
    Bouchla A; Sotiropoulou CD; Esteb C; Loupis T; Papageorgiou SG; Deliconstantinos GG; Pagoni M; Hatzimichael E; Dellatola M; Kalomoiri S; Apostolidou E; Kontos CK; Thomopoulos TP; Karantanos T; Pappa V
    Ann Hematol; 2024 Aug; 103(8):2853-2863. PubMed ID: 38842564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting GLI1 Suppresses Cell Growth and Enhances Chemosensitivity in CD34+ Enriched Acute Myeloid Leukemia Progenitor Cells.
    Long B; Wang LX; Zheng FM; Lai SP; Xu DR; Hu Y; Lin DJ; Zhang XZ; Dong L; Long ZJ; Tong XZ; Liu Q
    Cell Physiol Biochem; 2016; 38(4):1288-302. PubMed ID: 27008269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.
    Rao J; Xu DR; Zheng FM; Long ZJ; Huang SS; Wu X; Zhou WH; Huang RW; Liu Q
    J Transl Med; 2011 May; 9():71. PubMed ID: 21595920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
    Yao Y; Zhou J; Wang L; Gao X; Ning Q; Jiang M; Wang J; Wang L; Yu L
    PLoS One; 2013; 8(8):e70522. PubMed ID: 23940586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
    Tan M; Zhang Q; Yuan X; Chen Y; Wu Y
    J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia.
    Kong YL; Pan BH; Liang JH; Zhu HY; Wang L; Xia Y; Wu JZ; Fan L; Li JY; Xu W
    Aging (Albany NY); 2020 Aug; 12(16):16083-16098. PubMed ID: 32855355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia.
    Sanjiv K; Calderón-Montaño JM; Pham TM; Erkers T; Tsuber V; Almlöf I; Höglund A; Heshmati Y; Seashore-Ludlow B; Nagesh Danda A; Gad H; Wiita E; Göktürk C; Rasti A; Friedrich S; Centio A; Estruch M; Våtsveen TK; Struyf N; Visnes T; Scobie M; Koolmeister T; Henriksson M; Wallner O; Sandvall T; Lehmann S; Theilgaard-Mönch K; Garnett MJ; Östling P; Walfridsson J; Helleday T; Warpman Berglund U
    Cancer Res; 2021 Nov; 81(22):5733-5744. PubMed ID: 34593524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chidamide inhibits cell glycolysis in acute myeloid leukemia by decreasing N6-methyladenosine-related GNAS-AS1.
    Hu C; Fu X; Li S; Chen C; Zhao X; Peng J
    Daru; 2024 Jun; 32(1):11-24. PubMed ID: 37926762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis.
    Hassan HT; Zander A
    Acta Haematol; 1996; 95(3-4):257-62. PubMed ID: 8677752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells.
    Jin J; Mao S; Li F; Li X; Huang X; Yu M; Guo W; Jin J
    Med Oncol; 2019 Aug; 36(9):77. PubMed ID: 31372848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia.
    Strese S; Hassan SB; Velander E; Haglund C; Höglund M; Larsson R; Gullbo J
    Oncotarget; 2017 Jan; 8(4):6341-6352. PubMed ID: 27974676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
    Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
    Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iron Oxide Nanoparticles Combined with Cytosine Arabinoside Show Anti-Leukemia Stem Cell Effects on Acute Myeloid Leukemia by Regulating Reactive Oxygen Species.
    Dou J; Li L; Guo M; Mei F; Zheng D; Xu H; Xue R; Bao X; Zhao F; Zhang Y
    Int J Nanomedicine; 2021; 16():1231-1244. PubMed ID: 33633448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.